
G1 Therapeutics GTHX
Quarterly report 2024-Q2
added 08-08-2024
G1 Therapeutics Long Term Debt Current 2011-2025 | GTHX
Annual Long Term Debt Current G1 Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.28 M | 1.14 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.28 M | 1.14 M | 1.21 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | ||
|
Ascendis Pharma A/S
ASND
|
14.2 M | $ 220.27 | 4.81 % | $ 5 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 0.28 | -2.28 % | $ 609 M | ||
|
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.3 | -3.51 % | $ 7.94 B | ||
|
Aptorum Group Limited
APM
|
433 K | $ 1.29 | -3.01 % | $ 7.03 M | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
481 K | $ 3.26 | -3.12 % | $ 252 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 25.27 | -2.43 % | $ 1.22 B | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
Anika Therapeutics
ANIK
|
1.6 M | $ 9.57 | 0.84 % | $ 140 M | ||
|
BioNTech SE
BNTX
|
39.5 M | $ 94.73 | -1.32 % | $ 27.2 B | ||
|
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | ||
|
Axon Enterprise
AXON
|
9.45 M | $ 566.18 | -2.56 % | $ 42.9 B | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
137 K | $ 2.34 | 2.59 % | $ 14.7 M | ||
|
AstraZeneca PLC
AZN
|
339 M | $ 89.78 | -0.57 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 11.54 | 0.87 % | $ 746 M | ||
|
Biogen
BIIB
|
86.4 M | $ 174.42 | 1.11 % | $ 25.4 B | ||
|
BioVie
BIVI
|
74.5 K | $ 1.42 | -5.96 % | $ 2.1 M | ||
|
Abeona Therapeutics
ABEO
|
998 K | $ 5.36 | -2.99 % | $ 115 M | ||
|
Dynavax Technologies Corporation
DVAX
|
4.18 M | $ 10.85 | -0.14 % | $ 1.41 B | ||
|
ADiTx Therapeutics
ADTX
|
683 K | $ 2.3 | -3.0 % | $ 30.3 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
BioLineRx Ltd.
BLRX
|
522 K | $ 3.17 | -1.86 % | $ 908 M | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M |